Effects of Interleukin-1β Inhibition on Incident Hip and Knee Replacement : Exploratory Analyses From a Randomized, Double-Blind, Placebo-Controlled Trial.

ABSTRACT:

Background

Osteoarthritis is a common inflammatory disorder with no disease-modifying therapies. Whether inhibition of interleukin-1β (IL-1β) can reduce the consequences of large joint osteoarthritis is unclear.

Objective

To determine whether IL-1β inhibition with canakinumab reduces incident total hip or knee replacement (THR/TKR).

Design

Exploratory analysis of a randomized trial. (ClinicalTrials.gov: NCT01327846).

Setting

1091 clinical sites in 39 countries.

Participants

10 061 CANTOS (Canakinumab Anti-inflammatory Thrombosis Outcomes Study) participants.

Intervention

Random allocation to placebo or canakinumab (50, 150, or 300 mg) subcutaneously once every 3 months.

Measurements

The primary and secondary outcomes were time to first inci

SUBMITTER: Schieker M 

PROVIDER: S-EPMC8503784 | biostudies-literature | 2020 Oct

REPOSITORIES: biostudies-literature